Literature DB >> 15182256

Interleukin-10-modulated immature dendritic cells control the proinflammatory environment in multiple sclerosis.

S B Adikari1, A Pettersson, M Soderstrom, Y-M Huang, H Link.   

Abstract

Multiple sclerosis (MS) is a disabling, inflammatory, demyelinating disease of the central nervous system considered to be mediated by autoreactive T cells. Dendritic cells (DC), being professional antigen-presenting cells, play a pivotal role in the decision between T-cell activation and anergy. It has been suggested that mature DC (mDC) induce immunity, whereas immature DC (imDC) have the potential to induce tolerance. In this study, we investigated the effects of autologous imDC versus autologous mDC on lymphocytes with respect to the expression of functionally important cell-surface molecules and production of cytokines. Our aims were to investigate whether the maturation status of DC differs between MS and healthy controls (HC) and to explore whether the effects of DC on T-cell responses differ between MS and HC. DC were generated from adherent blood mononuclear cells from patients with MS and HC. imDC were obtained by culture with either granulocyte-macrophage colony-stimulating factor (GM-CSF) + interleukin-4 (IL-4) or GM-CSF + IL-4 + IL-10. mDC were obtained by adding lipopolysaccharide to DC cultures. Upon coculture with autologous lymphocytes, mDC activated the autologous T cells as reflected by increased CD25 and cytotoxic T-lymphocyte antigen-4 expression on CD4(+) T cells together with the increased production of both T helper 1 (Th1) (IL-2 and interferon-gamma) and Th2 (IL-10 and IL-4) cytokines. Unmodulated naïve imDC induced the production of only IL-4. An exposure of imDC to IL-10 induced the production of IL-4 as well as IL-10 by autologous lymphocytes. We hypothesize that such imDC are important in controlling the proinflammatory environment in vivo in patients with MS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15182256     DOI: 10.1111/j.1365-3083.2004.01453.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  8 in total

Review 1.  CXCL12 in control of neuroinflammation.

Authors:  Miljana Momcilović; Marija Mostarica-Stojković; Djordje Miljković
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

2.  A novel subset of helper T cells promotes immune responses by secreting GM-CSF.

Authors:  J Zhang; A I Roberts; C Liu; G Ren; G Xu; L Zhang; S Devadas; Yufang Shi
Journal:  Cell Death Differ       Date:  2013-09-27       Impact factor: 15.828

3.  Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response.

Authors:  Jerome J Graber; David Ford; Min Zhan; Gordon Francis; Hillel Panitch; Suhayl Dhib-Jalbut
Journal:  J Neuroimmunol       Date:  2007-02-27       Impact factor: 3.478

Review 4.  Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis.

Authors:  Zhong-Xiang Xie; Hong-Liang Zhang; Xiu-Juan Wu; Jie Zhu; Di-Hui Ma; Tao Jin
Journal:  Mediators Inflamm       Date:  2015-01-29       Impact factor: 4.711

5.  Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion.

Authors:  Stéphanie A Demoulin; Joan Somja; Anaëlle Duray; Samuel Guénin; Patrick Roncarati; Philippe O Delvenne; Michael F Herfs; Pascale M Hubert
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

6.  Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid-Results from the ToFingo Successor Study.

Authors:  Lisa Lohmann; Claudia Janoschka; Andreas Schulte-Mecklenbeck; Svenja Klinsing; Lucienne Kirstein; Uta Hanning; Timo Wirth; Tilman Schneider-Hohendorf; Nicholas Schwab; Catharina C Gross; Maria Eveslage; Sven G Meuth; Heinz Wiendl; Luisa Klotz
Journal:  Front Immunol       Date:  2018-07-09       Impact factor: 7.561

7.  A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines.

Authors:  Paulina García-González; Rodrigo Morales; Lorena Hoyos; Jaxaira Maggi; Javier Campos; Bárbara Pesce; David Gárate; Milton Larrondo; Rodrigo González; Lilian Soto; Verónica Ramos; Pía Tobar; María Carmen Molina; Karina Pino-Lagos; Diego Catalán; Juan Carlos Aguillón
Journal:  J Transl Med       Date:  2013-05-24       Impact factor: 5.531

8.  Dexamethasone and Monophosphoryl Lipid A-Modulated Dendritic Cells Promote Antigen-Specific Tolerogenic Properties on Naive and Memory CD4+ T Cells.

Authors:  Jaxaira Maggi; Katina Schinnerling; Bárbara Pesce; Catharien M Hilkens; Diego Catalán; Juan C Aguillón
Journal:  Front Immunol       Date:  2016-09-19       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.